AbCellera Biologics (ABCL) stock price is $11.93, up 1.10% on the day, as of Oct 19, 2026. It has a market cap of $3.64Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.64 Bn
P/E-22.13
P/S55.06
Div. Yield0.00
Revenue Growth (1y) (Qtr)-76.29
Add ratio to table…
About
AbCellera Biologics Inc. is a clinical stage biotechnology company dedicated to discovering and developing first in class antibody medicines for indications with high unmet medical need. The company has built a proprietary platform that enables the identification and optimization of antibodies against challenging targets such as G protein coupled receptors ion channels multispecific formats and antibody drug conjugates. AbCellera uses this platform to advance its own…
AbCellera Biologics Inc. is a clinical stage biotechnology company dedicated to discovering and developing first in class antibody medicines for indications with high unmet medical need. The company has built a proprietary platform that enables the identification and optimization of antibodies against challenging targets such as G protein coupled receptors ion channels multispecific formats and antibody drug conjugates. AbCellera uses this platform to advance its own internal pipeline while also providing antibody discovery and development services to pharmaceutical and biotechnology partners. As of the end of 2025 the company had 2 clinical candidates 2 pre IND candidates and more than 20 active discovery programs across multiple therapeutic areas. Since its inception AbCellera has invested approximately $1 billion in building its antibody discovery and development capabilities which include a 130,000 square foot clinical scale manufacturing facility completed in 2025. As of the end of 2025 the company employed approximately 562 full time staff across its sites in Canada Australia and the United States.
AbCellera generates revenue primarily through its partnership model which includes upfront payments for access research and intellectual property rights, milestone payments tied to preclinical clinical and regulatory achievements, and royalties on the net sales of commercialized medicines derived from its antibodies. The company may also receive out licensing payments and other downstream interests such as equity or co investment rights in its collaborators programs. As of December 31 2025 AbCellera reported approximately $700 million in available liquidity and has received a total of $475.6 million in non dilutive government financing to support platform construction and pipeline development. While the company does not yet have product sales and expects to operate at a loss in the near to medium term it anticipates future revenue from milestone achievements and royalty streams as its partnered and internal programs advance toward commercialization. As of December 31 2025 AbCellera had initiated 104 partner involvement programs that carry the potential for milestone payments and royalty participation. The reported average royalty rate across these programs is 3.3% with a range that has increased over time reflecting the greater value the company contributes to later stage collaborations. The company expects that as these programs progress through clinical development and toward commercialization it will receive milestone payments and royalties that will become a growing source of future revenue.
AbCellera occupies a differentiated niche in the biotechnology industry by focusing on historically difficult targets such as G protein coupled receptors and ion channels where conventional antibody approaches have limited success. Its competitive advantages stem from an integrated discovery engineering and manufacturing platform the application of artificial intelligence to improve screening and design and full control over its supply chain through a newly completed 130,000 square foot clinical scale manufacturing facility. The company faces competition from large pharmaceutical and biotechnology firms that are also pursuing antibody based therapies including Astellas Pharma Bayer Regeneron Sanofi Eli Lilly AbbVie Pfizer Kyowa Kirin Apogee Therapeutics and Bristol Myers Squibb particularly in the areas of vasomotor symptoms and atopic dermatitis. AbCellera seeks to distinguish itself by advancing first in class candidates that may offer improvements in safety dosing frequency and efficacy compared with existing treatments. According to industry data the global therapeutic antibody market reached approximately $300 billion in 2025 and is projected to exceed $500 billion by 2030 representing a compound annual growth rate above 10%. AbCellera’s focus on difficult targets such as G protein coupled receptors and ion channels positions it to capture a share of this expanding market where many competitors have historically struggled. The company also highlights its ability to generate multispecific antibodies and T cell engagers as additional differentiators that broaden its addressable opportunity.
AbCellera’s customer base consists chiefly of pharmaceutical and biotechnology companies that collaborate with the company to leverage its antibody discovery engine. Notable partners include AbbVie Eli Lilly Biogen Viking Global Investors ArrowMark Partners Regeneron Incyte Gilead Sciences Moderna and EQRx among many others. In addition to serving external collaborators AbCellera develops its own pipeline of drug candidates intended to treat patients suffering from conditions such as menopausal vasomotor symptoms atopic dermatitis autoimmune disorders and cancer. Although AbCellera does not currently sell medicines directly to patients its partnered programs are designed to deliver therapies to individuals with high unmet medical needs across multiple therapeutic areas. The company’s strategy is to retain economic interests in the success of these collaborations through royalties milestone payments and other downstream stakes so that its financial performance is linked to the eventual commercialization of the medicines it helps create.
Sector:HealthcareSector rationaleAbCellera is a biotechnology company that discovers and develops antibody medicines, fitting squarely within the Pharmaceuticals and Biotechnology industries of the Healthcare sector. Its revenue model is based on providing antibody discovery services to pharmaceutical partners and developing its own internal pipeline of drug candidates, with income derived from upfront payments, milestones, and royalties.Industries:BiotechnologyBiotechnologyPrimaryAbCellera is a clinical-stage biotechnology company that researches and develops antibody medicines, including multispecific formats and antibody-drug conjugates. Its revenue model is based on biologic-focused partnership payments, milestones, and royalties from collaborators like Eli Lilly and Regeneron.Contract ResearchContract ResearchSecondaryThe company provides antibody discovery and development services to pharmaceutical and biotechnology partners, acting as a contract research provider for identifying and optimizing antibodies against challenging targets.Classified using BQ-MICSCIK: 0001703057
Bull & bear
Investment Thesis
▲ Bull case
AbCellera Biologics' ABCL-635 program represents a significant near-term value inflection point that is underappreciated by the market. The interim Phase I data demonstrated sustained testosterone suppression of 50% to more than 75% for several weeks at doses of 300 mg, 600 mg, and 900 mg, directly comparable or superior to the approved small molecule fezolinetant, with a favorable safety profile showing no serious adverse events or liver toxicity. The pharmacokinetic profile supports a convenient once-monthly subcutaneous dosing regimen, addressing key patient adherence challenges in the vasomotor symptoms market. With top-line Phase II efficacy data expected in Q3 FY26, a positive readout would substantially de-risk the program and validate the first-in-class antibody approach for a $6 billion annual U.S. addressable market in non-hormonal VMS treatments, with additional upside potential in oncology-induced VMS markets where current therapies are poorly tolerated. Management explicitly stated that success in the Phase II portion would be highly de-risking, and the company has sufficient liquidity to fund at least the next three years of pipeline investments, reducing near-term financing concerns.
Beyond ABCL-635, AbCellera's strategic shift toward internal proprietary programs is gaining momentum with multiple near-term catalysts that are not fully reflected in current valuations. The company reported being on track to initiate up to three new clinical-stage programs by 2027 beyond current disclosed assets, including the undisclosed programs ABCL-688 and ABCL-386, which are advancing through IND-enabling activities. The selection of a fifth development candidate is expected in the first half of FY26, with ABCL-575 Phase I top-line data anticipated in Q4 FY26. This pipeline expansion is supported by substantially completed infrastructure projects and a strong liquidity position of approximately $655 million in available funds, including $530 million in cash and equivalents and $125 million in committed government funding. The reduction in sales, general, and administrative expenses by over 35% year-over-year, largely due to the resolution of intellectual property litigation, further strengthens the financial foundation for internal pipeline advancement without dilution risk.
AbCellera's platform efficiency and downstream partnership model provide a structural advantage that is underrecognized in the current market sentiment. Despite a reported decrease in partner-led programs with downstream participation from 44 to 40, the company maintains 14 molecules in the clinic with downstream stakes, indicating sustained validation of its discovery engine. The focus on internal programs does not abandon the partnership model; rather, it leverages the platform's proven ability to generate high-quality clinical candidates while retaining economic upside. The appointment of Dr. Victor Sandor to the Board of Directors adds significant oncology and clinical development expertise, enhancing the company's ability to advance programs like ABCL-635 into oncology-induced VMS indications and navigate late-stage development. This governance strengthening, combined with the platform's track record, positions AbCellera to capitalize on the growing demand for first-in-class biologics in large therapeutic areas without the capital intensity of de novo discovery.
AbCellera Biologics' ABCL-635 program represents a significant near-term value inflection point that is underappreciated by the market. The interim Phase I data demonstrated sustained testosterone suppression of 50% to more than 75% for several weeks at doses of 300 mg, 600 mg, and 900 mg, directly comparable or superior to the approved small molecule fezolinetant, with a favorable safety profile showing no serious adverse events or liver toxicity. The pharmacokinetic profile supports a convenient once-monthly subcutaneous dosing regimen, addressing key patient adherence challenges in the vasomotor symptoms market. With top-line Phase II efficacy data expected in Q3 FY26, a positive readout would substantially de-risk the program and validate the first-in-class antibody approach for a $6 billion annual U.S. addressable market in non-hormonal VMS treatments, with additional upside potential in oncology-induced VMS markets where current therapies are poorly tolerated. Management explicitly stated that success in the Phase II portion would be highly de-risking, and the company has sufficient liquidity to fund at least the next three years of pipeline investments, reducing near-term financing concerns.
Beyond ABCL-635, AbCellera's strategic shift toward internal proprietary programs is gaining momentum with multiple near-term catalysts that are not fully reflected in current valuations. The company reported being on track to initiate up to three new clinical-stage programs by 2027 beyond current disclosed assets, including the undisclosed programs ABCL-688 and ABCL-386, which are advancing through IND-enabling activities. The selection of a fifth development candidate is expected in the first half of FY26, with ABCL-575 Phase I top-line data anticipated in Q4 FY26. This pipeline expansion is supported by substantially completed infrastructure projects and a strong liquidity position of approximately $655 million in available funds, including $530 million in cash and equivalents and $125 million in committed government funding. The reduction in sales, general, and administrative expenses by over 35% year-over-year, largely due to the resolution of intellectual property litigation, further strengthens the financial foundation for internal pipeline advancement without dilution risk.
AbCellera's platform efficiency and downstream partnership model provide a structural advantage that is underrecognized in the current market sentiment. Despite a reported decrease in partner-led programs with downstream participation from 44 to 40, the company maintains 14 molecules in the clinic with downstream stakes, indicating sustained validation of its discovery engine. The focus on internal programs does not abandon the partnership model; rather, it leverages the platform's proven ability to generate high-quality clinical candidates while retaining economic upside. The appointment of Dr. Victor Sandor to the Board of Directors adds significant oncology and clinical development expertise, enhancing the company's ability to advance programs like ABCL-635 into oncology-induced VMS indications and navigate late-stage development. This governance strengthening, combined with the platform's track record, positions AbCellera to capitalize on the growing demand for first-in-class biologics in large therapeutic areas without the capital intensity of de novo discovery.